Literature DB >> 25408790

Delivering high-quality care to patients with muscle-invasive bladder cancer: Insights from routine practice in Ontario.

Christopher M Booth1, D Robert Siemens2.   

Abstract

Entities:  

Year:  2014        PMID: 25408790      PMCID: PMC4216280          DOI: 10.5489/cuaj.2339

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN: 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  22 in total

1.  Hospital volume and surgical mortality in the United States.

Authors:  John D Birkmeyer; Andrea E Siewers; Emily V A Finlayson; Therese A Stukel; F Lee Lucas; Ida Batista; H Gilbert Welch; David E Wennberg
Journal:  N Engl J Med       Date:  2002-04-11       Impact factor: 91.245

Review 2.  Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials.

Authors:  Jeffrey J Leow; William Martin-Doyle; Padma S Rajagopal; Chirayu G Patel; Erin M Anderson; Andrew T Rothman; Richard J Cote; Yuksel Urun; Steven L Chang; Toni K Choueiri; Joaquim Bellmunt
Journal:  Eur Urol       Date:  2013-08-28       Impact factor: 20.096

3.  Neoadjuvant chemotherapy should be administered to fit patients with newly diagnosed, potentially resectable muscle-invasive urothelial cancer of the bladder (MIBC): A 2013 CAGMO Consensus Statement and Call for a Streamlined Referral Process.

Authors:  Jo-An Seah; Normand Blais; Scott North; Yasmin Rahim; Dean Ruether; Peter C Black; Alexandre R Zlotta; Lori Wood; Srikala S Sridhar
Journal:  Can Urol Assoc J       Date:  2013 Sep-Oct       Impact factor: 1.862

Review 4.  Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines.

Authors:  Arnulf Stenzl; Nigel C Cowan; Maria De Santis; Markus A Kuczyk; Axel S Merseburger; Maria José Ribal; Amir Sherif; J Alfred Witjes
Journal:  Eur Urol       Date:  2011-03-23       Impact factor: 20.096

5.  Regional differences in practice patterns and outcomes in patients treated with radical cystectomy in a universal healthcare system.

Authors:  Bassel G Bachir; Armen G Aprikian; Yves Fradet; Joseph L Chin; Jonathan Izawa; Ricardo Rendon; Eric Estey; Adrian Fairey; Ilias Cagiannos; Louis Lacombe; Jean-Baptiste Lattouf; David Bell; Fred Saad; Darrel Drachenberg; Wassim Kassouf
Journal:  Can Urol Assoc J       Date:  2013 Nov-Dec       Impact factor: 1.862

6.  Patterns of referral for perioperative chemotherapy among patients with muscle-invasive bladder cancer: a population-based study.

Authors:  Christopher M Booth; David Robert Siemens; Yingwei Peng; William J Mackillop
Journal:  Urol Oncol       Date:  2014-06-23       Impact factor: 3.498

Review 7.  Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer.

Authors:  Cora N Sternberg; S Machele Donat; Joaquim Bellmunt; Randall E Millikan; Walter Stadler; Pieter De Mulder; Amir Sherif; Hans von der Maase; Taiji Tsukamoto; Mark S Soloway
Journal:  Urology       Date:  2007-01       Impact factor: 2.649

Review 8.  Radiotherapy for bladder cancer.

Authors:  Michael Milosevic; Mary Gospodarowicz; Anthony Zietman; Farhat Abbas; Karin Haustermans; Luc Moonen; Claus Rödel; Mark Schoenberg; William Shipley
Journal:  Urology       Date:  2007-01       Impact factor: 2.649

9.  Hospital volume and late survival after cancer surgery.

Authors:  John D Birkmeyer; Yating Sun; Sandra L Wong; Therese A Stukel
Journal:  Ann Surg       Date:  2007-05       Impact factor: 12.969

10.  Delivery of perioperative chemotherapy for bladder cancer in routine clinical practice.

Authors:  C M Booth; D R Siemens; Y Peng; I F Tannock; W J Mackillop
Journal:  Ann Oncol       Date:  2014-06-10       Impact factor: 32.976

View more
  2 in total

1.  Raising the bar for bladder cancer care.

Authors:  D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2016 Mar-Apr       Impact factor: 1.862

2.  Is there a measurable association of epidural use at cystectomy and postoperative outcomes? A population-based study.

Authors:  R Christopher Doiron; Melanie Jaeger; Christopher M Booth; Xuejiao Wei; D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2016 Sep-Oct       Impact factor: 1.862

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.